A study demonstrated efficient delivery of salinomycin to the EGFR−overexpressing osteosarcoma CSCs and cancer cells, which led to a reduced CSC population on osteosarcoma cells and CSCs by EGFR aptamer-bound, salinomycin-loaded polymer-lipid hybrid nanocarriers (EGFR-SNCs) (416). The gene discussed is EGFR; the disease is osteosarcoma.